Future Proofing Against Forever Chemicals: Navigating the Impact of a PFAS Ban on Parenteral Packaging

By Datwyler

PFAS are a large category of synthetic substances known for their strong fluorine-carbon bonds – a significant advantage in many pharmaceutical applications but a major concern when it comes to their environmental impact. With a potential EU-wide ban on the horizon, this whitepaper considers the potential impact on pharmaceutical supply chains, including information on how Datwyler – a leading provider of elastomer seals for parenteral packaging – is navigating the situation.

Enter your details below to view the free Whitepaper

By downloading this case study, you acknowledge that GlobalData may share your information with Datwyler and that your personal data will be used as described in their Privacy Policy

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Sections

Sections

Sections

Sections

Sections